{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T12:45:33Z","timestamp":1774788333502,"version":"3.50.1"},"reference-count":40,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1562,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1111\/j.1440-1681.2011.05492.x","type":"journal-article","created":{"date-parts":[[2011,2,3]],"date-time":"2011-02-03T18:30:04Z","timestamp":1296757804000},"page":"358-364","source":"Crossref","is-referenced-by-count":30,"title":["Activation of peroxisome proliferator-activated receptor-\u03b3 downregulates soluble epoxide hydrolase in cardiomyocytes"],"prefix":"10.1111","volume":"38","author":[{"given":"Wei","family":"Pang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ding","family":"Ai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Lin","family":"Niu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"You-Fei","family":"Guan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,5,23]]},"reference":[{"key":"10.1111\/j.1440-1681.2011.05492.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1159\/000006743","article-title":"Assessment of the coronary artery disease and systolic dysfunction in hypertensive patients with the dobutamine-atropine stress echocardiography: Effect of the left ventricular hypertrophy","volume":"89","author":"Ho","year":"1998","journal-title":"Cardiology"},{"key":"10.1111\/j.1440-1681.2011.05492.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1161\/01.RES.0000077012.11088.BC","article-title":"Phenotyping hypertrophy: Eschew obfuscation","volume":"92","author":"Dorn","year":"2003","journal-title":"Circ. Res."},{"key":"10.1111\/j.1440-1681.2011.05492.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0092-8674(00)80043-4","article-title":"Stress pathways and heart failure","volume":"98","author":"Chien","year":"1999","journal-title":"Cell"},{"key":"10.1111\/j.1440-1681.2011.05492.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0163-7827(03)00049-3","article-title":"Epoxyeicosatrienoic acids (EETs): Metabolism and biochemical function","volume":"43","author":"Spector","year":"2004","journal-title":"Prog. Lipid Res."},{"key":"10.1111\/j.1440-1681.2011.05492.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1152\/physrev.00021.2001","article-title":"P-450 metabolites of arachidonic acid in the control of cardiovascular function","volume":"82","author":"Roman","year":"2002","journal-title":"Physiol. Rev."},{"key":"10.1111\/j.1440-1681.2011.05492.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"36059","DOI":"10.1074\/jbc.R100030200","article-title":"Epoxygenase pathways of arachidonic acid metabolism","volume":"276","author":"Zeldin","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1111\/j.1440-1681.2011.05492.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1056\/NEJMra071667","article-title":"Myocardial reperfusion injury","volume":"357","author":"Yellon","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1111\/j.1440-1681.2011.05492.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"H2412","DOI":"10.1152\/ajpheart.00527.2004","article-title":"Effect of soluble epoxide hydrolase inhibition on epoxyeicosatrienoic acid metabolism in human blood vessels","volume":"287","author":"Fang","year":"2004","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1111\/j.1440-1681.2011.05492.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1073\/pnas.0811022106","article-title":"Soluble epoxide hydrolase plays an essential role in angiotensin II-induced cardiac hypertrophy","volume":"106","author":"Ai","year":"2009","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"10.1111\/j.1440-1681.2011.05492.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/sj.bjp.0703149","article-title":"Peroxisome proliferator-activated receptors in the cardiovascular system","volume":"129","author":"Bishop-Bailey","year":"2000","journal-title":"Br. J. Pharmacol."},{"key":"10.1111\/j.1440-1681.2011.05492.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1161\/01.HYP.0000084370.74777.B6","article-title":"Peroxisome proliferator-activated receptors: Vascular and cardiac effects in hypertension","volume":"42","author":"Schiffrin","year":"2003","journal-title":"Hypertension"},{"key":"10.1111\/j.1440-1681.2011.05492.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"8071","DOI":"10.1074\/jbc.272.12.8071","article-title":"Identification, characterization, and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoforms PPARgamma2 versus PPARgamma1 and activation with retinoid X receptor agonists and antagonists","volume":"272","author":"Mukherjee","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1111\/j.1440-1681.2011.05492.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3132\/dvdr.2005.010","article-title":"Thiazolidinediones, peripheral oedema and congestive heart failure: What is the evidence?","volume":"2","author":"Patel","year":"2005","journal-title":"Diab. Vasc. Dis. Res."},{"key":"10.1111\/j.1440-1681.2011.05492.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1291\/hypres.31.353","article-title":"Pioglitazone, a thiazolidinedione derivative, attenuates left ventricular hypertrophy and fibrosis in salt-sensitive hypertension","volume":"31","author":"Nakamoto","year":"2008","journal-title":"Hypertens. Res."},{"key":"10.1111\/j.1440-1681.2011.05492.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/08037050701396652","article-title":"Rosiglitazone reduces office and diastolic ambulatory blood pressure following 1-year treatment in non-diabetic subjects with insulin resistance","volume":"16","author":"Nilsson","year":"2007","journal-title":"Blood Press."},{"key":"10.1111\/j.1440-1681.2011.05492.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1161\/hc1002.105225","article-title":"Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo","volume":"105","author":"Asakawa","year":"2002","journal-title":"Circulation"},{"key":"10.1111\/j.1440-1681.2011.05492.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1111\/j.1463-1326.2008.00892.x","article-title":"Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials","volume":"10","author":"Mannucci","year":"2008","journal-title":"Diabetes Obes. Metab."},{"key":"10.1111\/j.1440-1681.2011.05492.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1073\/pnas.97.3.1196","article-title":"Targeted inhibition of calcineurin prevents agonist-induced cardiomyocyte hypertrophy","volume":"97","author":"Taigen","year":"2000","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"10.1111\/j.1440-1681.2011.05492.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1038\/bjp.2008.21","article-title":"Agonists at PPAR-gamma suppress angiotensin II-induced production of plasminogen activator inhibitor-1 and extracellular matrix in rat cardiac fibroblasts","volume":"153","author":"Hao","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"10.1111\/j.1440-1681.2011.05492.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/gene.10042","article-title":"Generation and functional confirmation of a conditional null PPARgamma allele in mice","volume":"32","author":"Jones","year":"2002","journal-title":"Genesis"},{"key":"10.1111\/j.1440-1681.2011.05492.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1128\/MCB.22.8.2607-2619.2002","article-title":"Conditional disruption of the peroxisome proliferator-activated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux","volume":"22","author":"Akiyama","year":"2002","journal-title":"Mol. Cell. Biol."},{"key":"10.1111\/j.1440-1681.2011.05492.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.tips.2004.03.012","article-title":"Peroxisome proliferator-activated receptor gamma in diabetes and metabolism","volume":"25","author":"Rangwala","year":"2004","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1111\/j.1440-1681.2011.05492.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1161\/hc4001.097186","article-title":"Peroxisome proliferator-activated receptor gamma activators inhibit cardiac hypertrophy in cardiac myocytes","volume":"104","author":"Yamamoto","year":"2001","journal-title":"Circulation"},{"key":"10.1111\/j.1440-1681.2011.05492.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1358\/dot.2003.39.5.799458","article-title":"The role of PPARgamma-dependent pathway in the development of cardiac hypertrophy","volume":"39","author":"Takano","year":"2003","journal-title":"Drugs Today"},{"issue":"Suppl 48","key":"10.1111\/j.1440-1681.2011.05492.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"16S","DOI":"10.1042\/CS103S016S","article-title":"Peroxisome proliferator-activated receptor-gamma activators inhibit endothelin-1-related cardiac hypertrophy in rats","volume":"103","author":"Sakai","year":"2002","journal-title":"Clin. Sci."},{"key":"10.1111\/j.1440-1681.2011.05492.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes","volume":"356","author":"Nissen","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1111\/j.1440-1681.2011.05492.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/S0140-6736(09)60953-3","article-title":"Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): A multicentre, randomised, open-label trial","volume":"373","author":"Home","year":"2009","journal-title":"Lancet"},{"key":"10.1111\/j.1440-1681.2011.05492.x-BIB28|cit28","volume-title":"Rosiglitazone and Outcomes for Patients with Diabetes and Coronary Artery Disease in the BARI 2D Trial","author":"Bach","year":"2010"},{"key":"10.1111\/j.1440-1681.2011.05492.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"14867","DOI":"10.1074\/jbc.M011761200","article-title":"Pathways of epoxyeicosatrienoic acid metabolism in endothelial cells. Implications for the vascular effects of soluble epoxide hydrolase inhibition","volume":"276","author":"Fang","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1111\/j.1440-1681.2011.05492.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0952-3278(97)90412-9","article-title":"Cytochrome P450 metabolites of arachidonic acid: Rapid incorporation and hydration of 14,15-epoxyeicosatrienoic acid in arterial smooth muscle cells","volume":"57","author":"Fang","year":"1997","journal-title":"Prostaglandins Leukot. Essent. Fatty Acids"},{"key":"10.1111\/j.1440-1681.2011.05492.x-BIB31|cit31","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1161\/01.HYP.0000153792.29478.1d","article-title":"Soluble epoxide hydrolase is a main effector of angiotensin II-induced hypertension","volume":"45","author":"Jung","year":"2005","journal-title":"Hypertension"},{"key":"10.1111\/j.1440-1681.2011.05492.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/FJC.0b013e318185fa3c","article-title":"Soluble epoxide hydrolase inhibitors reduce the development of atherosclerosis in apolipoprotein e-knockout mouse model","volume":"52","author":"Ulu","year":"2008","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1111\/j.1440-1681.2011.05492.x-BIB33|cit33","doi-asserted-by":"crossref","first-page":"H2128","DOI":"10.1152\/ajpheart.00428.2008","article-title":"Soluble epoxide hydrolase inhibition and gene deletion are protective against myocardial ischemia-reperfusion injury in vivo","volume":"295","author":"Motoki","year":"2008","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1111\/j.1440-1681.2011.05492.x-BIB34|cit34","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/ng.129","article-title":"Soluble epoxide hydrolase is a susceptibility factor for heart failure in a rat model of human disease","volume":"40","author":"Monti","year":"2008","journal-title":"Nat. Genet."},{"key":"10.1111\/j.1440-1681.2011.05492.x-BIB35|cit35","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1161\/hy0202.103788","article-title":"Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension","volume":"39","author":"Imig","year":"2002","journal-title":"Hypertension"},{"key":"10.1111\/j.1440-1681.2011.05492.x-BIB36|cit36","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1385\/CBB:47:1:87","article-title":"Prevention of hypertension in DOCA-salt rats by an inhibitor of soluble epoxide hydrolase","volume":"47","author":"Loch","year":"2007","journal-title":"Cell Biochem. Biophys."},{"key":"10.1111\/j.1440-1681.2011.05492.x-BIB37|cit37","doi-asserted-by":"crossref","first-page":"18733","DOI":"10.1073\/pnas.0609158103","article-title":"Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors","volume":"103","author":"Xu","year":"2006","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"10.1111\/j.1440-1681.2011.05492.x-BIB38|cit38","doi-asserted-by":"crossref","first-page":"9018","DOI":"10.1073\/pnas.0703229104","article-title":"Angiotensin II up-regulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo","volume":"104","author":"Ai","year":"2007","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"10.1111\/j.1440-1681.2011.05492.x-BIB39|cit39","doi-asserted-by":"crossref","first-page":"34176","DOI":"10.1074\/jbc.M203436200","article-title":"Constitutive activation of peroxisome proliferator-activated receptor-gamma suppresses pro-inflammatory adhesion molecules in human vascular endothelial cells","volume":"277","author":"Wang","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1111\/j.1440-1681.2011.05492.x-BIB40|cit40","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.bbagrm.2010.09.006","article-title":"DNA methylation of the promoter of soluble epoxide hydrolase silences its expression by an SP-1 dependent mechanism","volume":"1799","author":"Zhang","year":"2010","journal-title":"Biochim. Biophys. Acta"}],"container-title":["Clinical and Experimental Pharmacology and Physiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1440-1681.2011.05492.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1440-1681.2011.05492.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T20:39:05Z","timestamp":1712176745000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1440-1681.2011.05492.x"}},"subtitle":["PPAR\u03b3 downregulates sEH in heart"],"short-title":[],"issued":{"date-parts":[[2011,5,23]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,6]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1440-1681.2011.05492.x","relation":{},"ISSN":["0305-1870"],"issn-type":[{"value":"0305-1870","type":"print"}],"subject":[],"published":{"date-parts":[[2011,5,23]]}}}